<p>Thurston Springer Miller Herd  Titak Inc. 在最近向美国证券交易委员会（SEC）提交的文件中表示，在第三季度将其在 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免费报告) 的持仓降低了 91.2%。该基金在季度内出售了 2,487 股后，持有该制药公司 240 股股票。根据其最近的 SEC 文件，Thurston Springer Miller Herd  Titak Inc. 在 Vertex Pharmaceuticals 的持股价值为 94,000 美元。</p>
<ul>
<li>Royalty Pharma 如何在没有生物技术最大风险的情况下盈利</li>
</ul>
<p>其他机构投资者也对该公司的股份进行了增减。Costello Asset Management INC 在第二季度将其在 Vertex Pharmaceuticals 的股份增加了 3.6%。Costello Asset Management INC 目前持有 689 股该制药公司的股票，价值 307,000 美元，此前在上个季度又购买了 24 股。Kovack Advisors Inc. 在第二季度将其在 Vertex Pharmaceuticals 的持股增加了 1.9%。Kovack Advisors Inc. 目前持有 1,280 股该制药公司的股票，价值 570,000 美元，此前在该期间又购买了 24 股。Newman Dignan  Sheerar Inc. 在第二季度将其在 Vertex Pharmaceuticals 的股份增加了 3.3%。Newman Dignan  Sheerar Inc. 目前持有 786 股该制药公司的股票，价值 350,000 美元，此前在上个季度又购买了 25 股。Eastern Bank 在第二季度将其在 Vertex Pharmaceuticals 的持股增加了 1.6%。Eastern Bank 目前持有 1,635 股该制药公司的股票，价值 728,000 美元，此前在该期间又收购了 25 股。最后，Washington Trust Advisors Inc. 在第二季度将其在 Vertex Pharmaceuticals 的股份增加了 8.4%。Washington Trust Advisors Inc. 目前持有 323 股该制药公司的股票，价值 144,000 美元，此前在上个季度又收购了 25 股。90.96% 的股票由对冲基金和其他机构投资者持有。</p>
<p>获取 <strong>Vertex Pharmaceuticals</strong> 的提醒：</p>
<h2>内部人士下注</h2>
<p>在其他 Vertex Pharmaceuticals 的新闻中，执行副总裁 Charles F. Wagner, Jr. 于 12 月 3 日星期三出售了 14,000 股该公司的股票。股票以平均价格 456.00 美元出售，总交易额为 6,384,000.00 美元。出售后，该执行副总裁在公司持有 37,725 股，价值 17,202,600 美元。此交易代表其持股减少了 27.07%。该交易在向 SEC 提交的文件中披露，相关文件可通过此链接获取。此外，董事长 Jeffrey M. Leiden 于 12 月 3 日星期三出售了 63,781 股公司的股票。股票以平均价格 449.20 美元出售，总价值为 28,650,425.20 美元。交易完成后，董事长持有 24,026 股公司的股票，价值 10,792,479.20 美元。该交易使其持股减少了 72.64%。该销售的 SEC 文件提供了更多信息。在过去三个月中，内部人士出售了 151,073 股公司股票，价值 67,326,816 美元。0.20% 的股票由内部人士持有。</p>
<h2>Vertex Pharmaceuticals 股价下跌 1.2%</h2>
<ul>
<li>2025 年最佳生物技术股票</li>
</ul>
<p>VRTX 股票在星期四开盘价为 449.52 美元。该公司的 50 日移动平均线为 429.02 美元，200 日移动平均线为 425.79 美元。该股票的市值为 1,140.5 亿美元，市盈率为 31.70，贝塔值为 0.32。Vertex Pharmaceuticals Incorporated 的 1 年最低价为 362.50 美元，1 年最高价为 519.68 美元。</p>
<p>Vertex Pharmaceuticals (NASDAQ:VRTX - 获取免费报告) 最近于 11 月 3 日星期一发布了季度财报。该制药公司报告季度每股收益为 4.80 美元，超出分析师一致预期的 4.58 美元，超出幅度为 0.22 美元。该业务在季度内的收入为 30.8 亿美元，而分析师预期为 30.5 亿美元。Vertex Pharmaceuticals 的净利润率为 31.35%，股本回报率为 23.51%。该业务的季度收入较去年同期增长了 11.0%。在去年同期，该公司每股收益为 4.38 美元。作为一个整体，卖方分析师预测 Vertex Pharmaceuticals Incorporated 在当前财政年度将发布 15.63 美元的每股收益。</p>
<h2>分析师评级变动</h2>
<ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
<p>几位股票分析师最近对 VRTX 股票发表了看法。加拿大皇家银行在 11 月 4 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 423.00 美元下调至 415.00 美元，并对该公司给予了 “行业表现” 评级。摩根大通在 10 月 8 日的报告中将 Vertex Pharmaceuticals 的目标价从 517.00 美元上调至 530.00 美元，并给予该公司 “增持” 评级。Weiss Ratings 在 10 月 8 日的报告中重新发布了对 Vertex Pharmaceuticals 股票的 “持有（c+）” 评级。花旗集团在 10 月 2 日的研究报告中将 Vertex Pharmaceuticals 股票的目标价从 550.00 美元上调至 575.00 美元，并给予该公司 “买入” 评级。最后，华尔街禅在 8 月 22 日的报告中将 Vertex Pharmaceuticals 的评级从 “强烈买入” 下调至 “买入”。三位投资分析师对该股票给予了强烈买入评级，十五位给予了买入评级，十位对该公司的股票给予了持有评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，平均目标价为 498.42 美元。</p>
<p><strong>获取我们最新的 VRTX 股票报告</strong></p>
<h2>Vertex Pharmaceuticals 公司简介</h2>
<p>（免费报告）</p>
<p>Vertex Pharmaceuticals Incorporated 是一家生物技术公司，专注于开发和商业化治疗囊性纤维化（CF）的疗法。它为至少有一个 F508del 突变、年龄在 2 岁或以上的 CF 患者销售 TRIKAFTA/KAFTRIO；为年龄在 6 岁或以上的 CF 患者销售 SYMDEKO/SYMKEVI；为 1 岁或以上的 CF 患者销售 ORKAMBI；以及为 1 岁或以上的 CF 患者销售 KALYDECO，适用于 ivacaftor 治疗。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，胜过 Vertex Pharmaceuticals</li>
<li>FAANG 股票是什么？它们是好的投资吗？</li>
<li>在上涨 35% 后，分析师关注铜业巨头 Freeport 的更多上涨空间</li>
<li>能源和石油股票解析</li>
<li>为什么 SpaceX 的 IPO 可能成为 GOOGL 股票的主要催化剂</li>
<li>市值计算器：如何计算市值</li>
<li>Upwork 能否维持复苏？看涨和看跌的理由</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Vertex Pharmaceuticals 吗？</h2>
<p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Vertex Pharmaceuticals 并不在名单上。</p>
<p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

福泰制药

<p>Thurston Springer Miller Herd & Titak Inc. 在第三季度大幅减少了对 Vertex Pharmaceuticals 的持股，减持幅度达到 91.2%，出售了 2,487 股。该基金目前持有 240 股，市值为 94,000 美元。其他机构投资者也对 Vertex 调整了他们的持仓，其中一些增加了持股。包括执行副总裁 Charles F. Wagner, Jr. 和董事长 Jeffrey M. Leiden 在内的内部人士也出售了股份。Vertex 的股票开盘价为 449.52 美元，市值为 1,140.5 亿美元。该公司报告了强劲的季度收益，超出了分析师的预期</p>

<p>Thurston Springer Miller Herd &amp; Titak Inc. lowered its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 91.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 240 shares of the pharmaceutical company's stock after selling 2,487 shares during the quarter. Thurston Springer Miller Herd &amp; Titak Inc.'s holdings in Vertex Pharmaceuticals were worth $94,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Thurston Springer Miller Herd  Titak Inc. 在最近向美国证券交易委员会（SEC）提交的文件中表示，在第三季度将其在 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免费报告) 的持仓降低了 91.2%。该基金在季度内出售了 2,487 股后，持有该制药公司 240 股股票。根据其最近的 SEC 文件，Thurston Springer Miller Herd  Titak Inc. 在 Vertex Pharmaceuticals 的持股价值为 94,000 美元。</p>
</div><ul>
<li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li>
</ul>
<div class="lb-trans"><ul>
<li>Royalty Pharma 如何在没有生物技术最大风险的情况下盈利</li>
</ul>
</div><p>Other institutional investors have also added to or reduced their stakes in the company. Costello Asset Management INC increased its stake in shares of Vertex Pharmaceuticals by 3.6% in the second quarter. Costello Asset Management INC now owns 689 shares of the pharmaceutical company's stock worth $307,000 after purchasing an additional 24 shares in the last quarter. Kovack Advisors Inc. boosted its holdings in Vertex Pharmaceuticals by 1.9% in the 2nd quarter. Kovack Advisors Inc. now owns 1,280 shares of the pharmaceutical company's stock worth $570,000 after buying an additional 24 shares during the period. Newman Dignan &amp; Sheerar Inc. grew its stake in Vertex Pharmaceuticals by 3.3% in the 2nd quarter. Newman Dignan &amp; Sheerar Inc. now owns 786 shares of the pharmaceutical company's stock valued at $350,000 after buying an additional 25 shares in the last quarter. Eastern Bank raised its holdings in Vertex Pharmaceuticals by 1.6% during the 2nd quarter. Eastern Bank now owns 1,635 shares of the pharmaceutical company's stock valued at $728,000 after acquiring an additional 25 shares during the period. Finally, Washington Trust Advisors Inc. lifted its position in shares of Vertex Pharmaceuticals by 8.4% during the second quarter. Washington Trust Advisors Inc. now owns 323 shares of the pharmaceutical company's stock worth $144,000 after acquiring an additional 25 shares in the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他机构投资者也对该公司的股份进行了增减。Costello Asset Management INC 在第二季度将其在 Vertex Pharmaceuticals 的股份增加了 3.6%。Costello Asset Management INC 目前持有 689 股该制药公司的股票，价值 307,000 美元，此前在上个季度又购买了 24 股。Kovack Advisors Inc. 在第二季度将其在 Vertex Pharmaceuticals 的持股增加了 1.9%。Kovack Advisors Inc. 目前持有 1,280 股该制药公司的股票，价值 570,000 美元，此前在该期间又购买了 24 股。Newman Dignan  Sheerar Inc. 在第二季度将其在 Vertex Pharmaceuticals 的股份增加了 3.3%。Newman Dignan  Sheerar Inc. 目前持有 786 股该制药公司的股票，价值 350,000 美元，此前在上个季度又购买了 25 股。Eastern Bank 在第二季度将其在 Vertex Pharmaceuticals 的持股增加了 1.6%。Eastern Bank 目前持有 1,635 股该制药公司的股票，价值 728,000 美元，此前在该期间又收购了 25 股。最后，Washington Trust Advisors Inc. 在第二季度将其在 Vertex Pharmaceuticals 的股份增加了 8.4%。Washington Trust Advisors Inc. 目前持有 323 股该制药公司的股票，价值 144,000 美元，此前在上个季度又收购了 25 股。90.96% 的股票由对冲基金和其他机构投资者持有。</p>
</div><p>Get <strong>Vertex Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Vertex Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Vertex Pharmaceuticals news, EVP Charles F. Wagner, Jr. sold 14,000 shares of the firm's stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $456.00, for a total transaction of $6,384,000.00. Following the sale, the executive vice president owned 37,725 shares in the company, valued at $17,202,600. This trade represents a 27.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Chairman Jeffrey M. Leiden sold 63,781 shares of the company's stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $449.20, for a total value of $28,650,425.20. Following the completion of the transaction, the chairman owned 24,026 shares of the company's stock, valued at $10,792,479.20. The trade was a 72.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 151,073 shares of company stock worth $67,326,816. 0.20% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他 Vertex Pharmaceuticals 的新闻中，执行副总裁 Charles F. Wagner, Jr. 于 12 月 3 日星期三出售了 14,000 股该公司的股票。股票以平均价格 456.00 美元出售，总交易额为 6,384,000.00 美元。出售后，该执行副总裁在公司持有 37,725 股，价值 17,202,600 美元。此交易代表其持股减少了 27.07%。该交易在向 SEC 提交的文件中披露，相关文件可通过此链接获取。此外，董事长 Jeffrey M. Leiden 于 12 月 3 日星期三出售了 63,781 股公司的股票。股票以平均价格 449.20 美元出售，总价值为 28,650,425.20 美元。交易完成后，董事长持有 24,026 股公司的股票，价值 10,792,479.20 美元。该交易使其持股减少了 72.64%。该销售的 SEC 文件提供了更多信息。在过去三个月中，内部人士出售了 151,073 股公司股票，价值 67,326,816 美元。0.20% 的股票由内部人士持有。</p>
</div><h2>Vertex Pharmaceuticals Trading Down 1.2%</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 股价下跌 1.2%</h2>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年最佳生物技术股票</li>
</ul>
</div><p>VRTX stock opened at $449.52 on Thursday. The company's 50 day moving average is $429.02 and its 200 day moving average is $425.79. The stock has a market cap of $114.05 billion, a price-to-earnings ratio of 31.70 and a beta of 0.32. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.68.</p>
<div class="lb-trans"><p>VRTX 股票在星期四开盘价为 449.52 美元。该公司的 50 日移动平均线为 429.02 美元，200 日移动平均线为 425.79 美元。该股票的市值为 1,140.5 亿美元，市盈率为 31.70，贝塔值为 0.32。Vertex Pharmaceuticals Incorporated 的 1 年最低价为 362.50 美元，1 年最高价为 519.68 美元。</p>
</div><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 EPS for the quarter, topping analysts' consensus estimates of $4.58 by $0.22. The business had revenue of $3.08 billion during the quarter, compared to analysts' expectations of $3.05 billion. Vertex Pharmaceuticals had a net margin of 31.35% and a return on equity of 23.51%. The business's quarterly revenue was up 11.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.38 EPS. As a group, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals (NASDAQ:VRTX - 获取免费报告) 最近于 11 月 3 日星期一发布了季度财报。该制药公司报告季度每股收益为 4.80 美元，超出分析师一致预期的 4.58 美元，超出幅度为 0.22 美元。该业务在季度内的收入为 30.8 亿美元，而分析师预期为 30.5 亿美元。Vertex Pharmaceuticals 的净利润率为 31.35%，股本回报率为 23.51%。该业务的季度收入较去年同期增长了 11.0%。在去年同期，该公司每股收益为 4.38 美元。作为一个整体，卖方分析师预测 Vertex Pharmaceuticals Incorporated 在当前财政年度将发布 15.63 美元的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
</div><p>Several equities analysts have recently weighed in on VRTX shares. Royal Bank Of Canada reduced their price target on Vertex Pharmaceuticals from $423.00 to $415.00 and set a &#34;sector perform&#34; rating for the company in a research report on Tuesday, November 4th. JPMorgan Chase &amp; Co. lifted their target price on Vertex Pharmaceuticals from $517.00 to $530.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, October 8th. Weiss Ratings reissued a &#34;hold (c+)&#34; rating on shares of Vertex Pharmaceuticals in a report on Wednesday, October 8th. Citigroup raised their price objective on shares of Vertex Pharmaceuticals from $550.00 to $575.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, October 2nd. Finally, Wall Street Zen lowered shares of Vertex Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Friday, August 22nd. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $498.42.</p>
<div class="lb-trans"><p>几位股票分析师最近对 VRTX 股票发表了看法。加拿大皇家银行在 11 月 4 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 423.00 美元下调至 415.00 美元，并对该公司给予了 “行业表现” 评级。摩根大通在 10 月 8 日的报告中将 Vertex Pharmaceuticals 的目标价从 517.00 美元上调至 530.00 美元，并给予该公司 “增持” 评级。Weiss Ratings 在 10 月 8 日的报告中重新发布了对 Vertex Pharmaceuticals 股票的 “持有（c+）” 评级。花旗集团在 10 月 2 日的研究报告中将 Vertex Pharmaceuticals 股票的目标价从 550.00 美元上调至 575.00 美元，并给予该公司 “买入” 评级。最后，华尔街禅在 8 月 22 日的报告中将 Vertex Pharmaceuticals 的评级从 “强烈买入” 下调至 “买入”。三位投资分析师对该股票给予了强烈买入评级，十五位给予了买入评级，十位对该公司的股票给予了持有评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，平均目标价为 498.42 美元。</p>
</div><p><strong>Get Our Latest Stock Report on VRTX</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 VRTX 股票报告</strong></p>
</div><h2>Vertex Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals Incorporated 是一家生物技术公司，专注于开发和商业化治疗囊性纤维化（CF）的疗法。它为至少有一个 F508del 突变、年龄在 2 岁或以上的 CF 患者销售 TRIKAFTA/KAFTRIO；为年龄在 6 岁或以上的 CF 患者销售 SYMDEKO/SYMKEVI；为 1 岁或以上的 CF 患者销售 ORKAMBI；以及为 1 岁或以上的 CF 患者销售 KALYDECO，适用于 ivacaftor 治疗。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Vertex Pharmaceuticals</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li>
<li>Energy and Oil Stocks Explained</li>
<li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Vertex Pharmaceuticals</li>
<li>FAANG 股票是什么？它们是好的投资吗？</li>
<li>在上涨 35% 后，分析师关注铜业巨头 Freeport 的更多上涨空间</li>
<li>能源和石油股票解析</li>
<li>为什么 SpaceX 的 IPO 可能成为 GOOGL 股票的主要催化剂</li>
<li>市值计算器：如何计算市值</li>
<li>Upwork 能否维持复苏？看涨和看跌的理由</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VRTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Vertex Pharmaceuticals 吗？</h2>
</div><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Vertex Pharmaceuticals 并不在名单上。</p>
</div><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Thurston Springer Miller Herd & Titak Inc.出售了福泰制药公司（Vertex Pharmaceuticals Incorporated）的 2,487 股股票，股票代码为 VRTX